Business, energy, technology, markets and global industry news from Business News Today

NS Pharma

PharmaDeviceNews NS Pharma
Representative image: Laboratory research into EXG-7001 highlights Nippon Shinyaku and Elixirgen Therapeutics’ effort to develop a full-length dystrophin mRNA therapy for Duchenne muscular dystrophy.
Pharma & Biotech

Nippon Shinyaku backs EXG-7001 as full-length dystrophin mRNA strategy enters Duchenne race

Discover how Nippon Shinyaku’s EXG-7001 option could advance full-length dystrophin mRNA therapy for Duchenne muscular dystrophy.

Read More
Representative image of clinicians reviewing cardiac and upper-limb assessments as Capricor prepares deramiocel for a decisive FDA advisory committee in Duchenne muscular dystrophy.
Pharma & Biotech

Capricor faces an FDA panel for deramiocel, but has HOPE-3 truly resolved its Duchenne evidence gap?

Capricor Therapeutics has secured a July 29 FDA advisory committee meeting for deramiocel after a positive Phase 3 trial revived the previously rejected Duchenne muscular dystrophy application. The therapy now has controlled evidence of skeletal and cardiac benefit, but regulators must still weigh endpoint interpretation, long-term external comparisons, manufacturing reliability and whether the proposed label

Read More